Pathogens (Basel), 2023-10, Vol.12 (10), p.1221
2023
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- An Update on the Current State of SARS-CoV-2 Mac1 Inhibitors
- Ist Teil von
- Pathogens (Basel), 2023-10, Vol.12 (10), p.1221
- Ort / Verlag
- Switzerland: MDPI AG
- Erscheinungsjahr
- 2023
- Quelle
- EZB Electronic Journals Library
- Beschreibungen/Notizen
- Non-structural protein 3 (nsp3) from all coronaviruses (CoVs) contains a conserved macrodomain, known as Mac1, that has been proposed as a potential therapeutic target for CoVs due to its critical role in viral pathogenesis. Mac1 is an ADP-ribose binding protein and ADP-ribosylhydrolase that promotes replication and blocks IFN responses, though the precise mechanisms it uses to carry out these functions remain unknown. Over the past 3 years following the onset of COVID-19, several groups have used high-throughput screening with multiple assays and chemical modifications to create unique chemical inhibitors of the SARS-CoV-2 Mac1 protein. Here, we summarize the current efforts to identify selective and potent inhibitors of SARS-CoV-2 Mac1.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 2076-0817eISSN: 2076-0817DOI: 10.3390/pathogens12101221Titel-ID: cdi_doaj_primary_oai_doaj_org_article_6f5e6615ca144d4793a7b380b4af50a9
- Format
- –
- Schlagworte
- ADP-ribosylation, Antiviral agents, Binding sites, Chemical properties, coronavirus, Coronaviruses, COVID-19, Crystallography, Enzymes, High-throughput screening, Hydrogen bonds, Inhibitors, Ligands, Mac1, Mac1 protein, macrodomain, Middle East respiratory syndrome, Mutation, Pathogenesis, Pharmaceutical research, Physiological aspects, Proteins, Review, Ribose, SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2, Structure, Therapeutic targets, Viral proteins